The camptothecins. (Q35169644)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The camptothecins.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

Europe PubMed Central

The camptothecins (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Leonard B. Saltz

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

Joseph F Pizzolato

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

361

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

9376

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

2235-2242

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of topotecan administered five times daily in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of CPT-11 in combination with other anti-cancer agents in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913780-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(03)13780-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12842380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35169644&oldid=1623041708"